Divisions of Medical Oncology, Department of Medicine, and Urology, Duke University Medical Center, Durham, North Carolina, USA.
Sunitinib treatment benefits patients with metastatic renal cell carcinoma (mRCC), but response duration can vary widely and resistance is not predicted by standard measures. [¹⁸F]fluoro-2-deoxy-2-D-glucose positron emission tomography (FDG-PET) uptake is variable in mRCC, but changes in FDG-PET uptake may be useful in monitoring disease progression. Further work is needed to personalize treatment for patients with mRCC.
Written by:
Harrison MR, George DJ. Are you the author?
Reference: Clin Cancer Res. 2011 Sep 15;17(18):5841-3.
doi: 10.1158/1078-0432.CCR-11-1768
PubMed Abstract
PMID: 21926167
UroToday.com Renal Cancer Section
